Literature DB >> 9989666

A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19.

K Itoh1, K Inoue, S Yanagiwara, H Kyoya, T Suzuki.   

Abstract

A rapid and simple cytochrome P450 (CYP) 2C19 genotyping system was established by making several modifications in previously reported procedures. PCR conditions were modified to be capable of simultaneous amplification of CYP2C19m1 and CYP2C19m2 regions. Intensive bands of 169 bp for the CYP2C19m1 region and 329 bp for the CYP2C19m2 region with low background were obtained by using PCR condition involving an initial denaturation of 5 min at 94 degrees C, 35 cycles of 1 min at 94 degrees C; 1 min at 53 degrees C; 1 min at 72 degrees C, and final extension of 5 min at 72 degrees C. Next, the optimal restriction enzyme digestion conditions were determined by using PCR products from a subject of wt/wt genotype. Both products were completely digested with 5 U of the corresponding enzyme (Sma I for CYP2C19m1 and Bam HI for CYP2C19m2) for 1 h incubation at an optimal temperature. The incidence (16%; 5/32) of subjects homozygous for mutant alleles determined by an established assay system agreed well with the incidence of the poor metabolizer (PM) phenotype in the Japanese population. The established genotyping system would, therefore, be applicable to the clinical laboratory testing of patients with a PM phenotype of CYP2C19 to select appropriate and effective medication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989666     DOI: 10.1248/bpb.22.77

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  4 in total

Review 1.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.

Authors:  Yumiko Ohkubo; Akihito Ueta; Naoki Ando; Tetsuya Ito; Sachiko Yamaguchi; Kantaro Mizuno; Satoshi Sumi; Tohru Maeda; Daiju Yamazaki; Yukihisa Kurono; Shinji Fujimoto; Hajime Togari
Journal:  J Hum Genet       Date:  2005-11-24       Impact factor: 3.172

3.  Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.

Authors:  Masatomo Miura; Kazuyuki Inoue; Shigeru Satoh; Yoshihiko Itoh; Hideaki Kagaya; Hitoshi Tada; Yorihisa Tanaka; Tomonori Habuchi; Toshio Suzuki
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

4.  Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.

Authors:  Ram Lakhan; Ritu Kumari; Kavita Singh; Jayanti Kalita; Usha Kant Misra; Balraj Mittal
Journal:  Indian J Med Res       Date:  2011-09       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.